Fundraising Fox

BioCircuit Technologies

Atlanta, US · Founded 2016 · Georgia corporation · 1 known investors

biocircuit.com

Founders & leadership

JN
James NahirnyDirector
TO
Thomas O'BrienExecutive Officer, Director
MJ
Michelle JarrardExecutive Officer, Director

Investors · 1

Reported raises · per SEC filings

Form D private placements
$9MraisedOct 2022 · 33 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michelle JarrardExecutive Officer, Director
  • James NahirnyDirector
  • Michael MastersDirector
  • Thomas O'BrienDirector
Offering amount
$9M
Amount sold
$9M
First sale
Sep 2022
Incorporated
Corporation, Georgia
Federal exemptions
04, 06b
Full filing on SEC EDGAR ↗
$3.1MraisedApr 2021 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James NahirnyDirector
  • Michael MastersDirector
  • Thomas O'BrienDirector
  • Michelle JarrardExecutive Officer, Director
Offering amount
$3.1M
Amount sold
$3.1M
First sale
Apr 2021
Incorporated
Corporation, Georgia, 2016
Federal exemptions
04, 06b
Full filing on SEC EDGAR ↗
$1.5MraisedApr 2021 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michelle JarrardExecutive Officer, Director
  • James NahirnyDirector
  • Thomas O'BrienExecutive Officer, Director
Offering amount
$1.5M
Amount sold
$1.5M
First sale
May 2019
Incorporated
Corporation, Georgia, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1.9M
National Institutes of Health (NIH)National Institutes of HealthPhase II2023$1.1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$1.9M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.